The Solution
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
Careers
Sparking Transformation to Save Lives
Join the team working to improve the outcomes of every cardiovascular patient in the United States.
We are aware of fraudulent recruiting activity by individuals impersonating egnite. egnite exclusively posts available opportunities on LinkedIn. Any interviews will be scheduled by egnite’s Vice President of People and Culture, egnite’s Human Resources Specialist, or a recruitment firm that partners with egnite. All interviews will be conducted by phone or video interview, and egnite and our recruitment partners will never ask you to complete an interview through email. Please report any suspicious recruiting activities to ciso@egnitehealth.com.
The Solution
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
Culture
egniter
(noun): egnite employees are passionate about their role as technologists and scientists. We thrive on the excitement of discovery - especially discoveries that will impact patient lives.
We are:

BOLD
We are bold, with the provenance, people and technology required to change healthcare for the better.

TECH FORWARD
We are tech forward - as digital evangelists and groundbreakers, we relentlessly pursue new ways to apply technologies that improve patient care.

PASSIONATE
We are passionate - the future cannot come fast enough. We are passionate about our role as technologists and we thrive on the excitement of discovery.

CREDIBLE
We are credible - science is the basis of our business and healthcare is the industry we serve. Credibility is critical to both.
Passionate About Our People
At egnite, we recognize the importance of investing in our workforce. That is why we offer a total rewards package that we believe sets us apart. As part of this total rewards package, we have included dynamic and comprehensive benefits packages for our team. These benefits are designed to provide our employees and their families with additional financial protection, security and support for both their careers and personal lives. Here are just a few of the many benefits we offer:

Comprehensive Health Plans

Retirement Savings

Paid Time Off

Remote Work

Paid Parental Leave

Professional Development
Employee Testimonials
Hear from a few egniter’s on why they love the work they do!




egniter Profiles
Learn more about some of the egniter’s on our team!
Resources

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis
BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized, warranting further investigation. OBJECTIVES To […]

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams
On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.